-
LifeShield Medical Launches China HQ and Advanced Heart System Factory in Suzhou
•
LifeShield Medical, a leading Sino-German multinational medical device company, has announced the official operation of its China headquarters and a state-of-the-art interventional artificial heart system factory located in the Suzhou Industrial Park. This move signifies a major step forward in the company’s commitment to innovation and service within the Chinese…
-
Tencent’s WeDoctor Teams Up with Guiyang for Digital Health Community Initiative
•
The municipal government of Guiyang has entered into a strategic partnership with WeDoctor Holdings Ltd, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700), to establish a digital health community and develop a national demonstration zone in Guiyang. The collaboration also includes the launch of a health…
-
Sandoz Strikes Deal to Acquire Coherus Biosimilar for Ophthalmic Treatment
•
Swiss pharmaceutical company Sandoz (SWX: SDZ) has entered into an agreement to purchase Cimerli (ranibizumab), a biosimilar referencing Roche (SWX: RO) unit Genentech’s Lucentis, from US-based Coherus Biosciences (NASDAQ: CHRS). This transaction, valued at a USD 170 million upfront payment, is anticipated to conclude in the first half of 2024.…
-
HuidaGene Therapeutics’ CRISPR Therapy Earns Orphan Drug Status for Duchenne Muscular Dystrophy
•
China-based biotechnology company HuidaGene Therapeutics has announced that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its CRISPR-Cas12 DNA editing therapy, HG302, intended for the treatment of Duchenne muscular dystrophy (DMD), a severe and often fatal neuromuscular genetic disorder. This designation follows…
-
Pudong New Area Aims to Boost Healthcare with Comprehensive Reform Plan
•
The General Office of the CPC Central Committee and State Council has released the “Implementation Plan for Comprehensive Reform Pilot in Pudong New Area (2023-2027)”, outlining a series of measures aimed at enhancing the high-level opening-up and deepening reforms within the Shanghai municipality’s district. The plan targets the healthcare industry…
-
AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment
•
AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has received regulatory approval from the US Food and Drug Administration (FDA) for its respiratory drug Airsupra (albuterol + budesonide). The drug is now approved for the treatment or prevention of asthma symptoms and for the…
-
Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial
•
Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan) in metastatic or advanced non-small cell lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS) in patients who had previously received treatment for metastatic NSCLC. Despite this setback,…
-
NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions
•
The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023 Edition)”, marking a significant update to the 2022 version with the inclusion of recently approved drugs and refinements to drug indications and rational medication guidance. Since the establishment of the expert committee on rational drug…
